抗人P185^erbB2嵌合抗体的CHO细胞中的高效表达及其活性分析

为降低人抗鼠抗体（HAMA）反应并在CHO细胞中高效表达抗人P185^erbB2人／鼠嵌合抗体,将抗人P185^erbB2单抗C25的轻、重链可变区基因分别克隆入具有人抗体恒定区基因组序列和弱化启动子驱地劝的选择标志基因的真核表达载体中,共转染CHO－dhfr^-细胞,经G418及氨甲喋呤（MTX）梯度加压筛选进行了嵌合抗体的高效表达,采用RT－PCR、ELISA、细胞ELISA、免疫荧光细胞化等实验证实了所表达的抗人P185^erbB2嵌合抗体的人源性及抗原特异性。培养上清中的抗体产量可达100mg/L,所表达的嵌合抗体具有抑制P185^erbB2高表达肿瘤细胞增殖的作用。     

CHO细胞表达系统研究新进展

中国仓鼠卵巢细胞（Ｃｈｉｎｅｓｅ Ｈａｍｓｔｅｒ Ｏｖａｒｙ Ｃｅｌｌ）是上前重组糖基蛋白生产首选体系。本文综述近几年该系统在生产基因工程药物方面的研究进展、存在问题和发展方向。     

抗人P185~(erbB2)嵌合抗体在CHO细胞中的高效表达及其活性分析

为降低人抗鼠抗体 (HAMA)反应并在CHO细胞中高效表达抗人P185 erbB2 人 /鼠嵌合抗体 ,将抗人P185 erbB2 单抗C2 5的轻、重链可变区基因分别克隆入具有人抗体恒定区基因组序列和弱化启动子驱动的选择标志基因的真核表达载体中 ,共转染CHO dhfr-细胞 ,经G418及氨甲喋呤 (MTX)梯度加压筛选进行了嵌合抗体的高效表达。采用RT PCR、ELISA、细胞ELISA、免疫荧光细胞化学等实验证实了所表达的抗人P185 erbB2 嵌合抗体的人源性及抗原特异性。培养上清中的抗体产量可达 10 0mg/L ,所表达的嵌合抗体具有抑制P185 erbB2 高表达肿瘤细胞增殖的作用     

CHO细胞表达系统启动子

中国仓鼠卵巢（Chinese hamsters ovary,CHO）细胞是目前重组蛋白质生产的首选宿主细胞。利用CHO细胞生产重组蛋白质,启动子是启动转基因转录的关键。核心启动子是RNA聚合酶与转录起始复合物集合的部位,分为集中型和分散型两种类型。目前,CHO细胞常用的启动子为病毒启动子、异源启动子、内源性和诱导性启动子等。也可以利用合成生物学及相关的数据库,人工设计合成启动子及鉴定新型启动子。本文综述了CHO细胞常用的启动子以及人工设计的合成启动子在CHO细胞中重组蛋白质表达方面的进展,为哺乳动物细胞选择合适的启动子,保证蛋白质表达量最大化,并确保长时间表达稳定性提供参考。     

APRT缺陷型CHO细胞系的建立及其重组蛋白表达能力评价北大核心CSCD

中国仓鼠卵巢(Chinese hamster ovary,CHO)细胞是生产复杂重组药物蛋白的首选宿主细胞,腺嘌呤磷酸核糖转移酶(adenine phosphoribosyltransferase,APRT)催化腺嘌呤与磷酸核糖缩合形成腺苷一磷酸,是嘌呤生物合成步骤中的关键酶。采用基因编辑技术敲除CHO细胞中aprt基因,验证获得的APRT缺陷型CHO细胞系的生物学特性;构建两种真核表达载体:对照载体(含有目的基因增强型绿色荧光蛋白(enhanced green fluorescent protein,EGFP)和弱化载体(含有启动子和起始密码子突变的aprt弱化表达盒及EGFP),分别转染APRT缺陷型和野生型CHO细胞并筛选获得稳定转染的细胞池;重组CHO细胞传代培养60代并用流式细胞术检测EGFP表达的平均荧光强度,并比较不同实验组重组蛋白EGFP的表达稳定性。PCR扩增和测序结果表明,CHO细胞aprt基因成功敲除;获得的APRT缺陷型CHO细胞系在细胞形态、生长增殖、倍增时间等生物学特性方面与野生CHO细胞无显著差异。目的蛋白瞬时表达结果表明,与野生型CHO细胞相比,转染对照载体和弱化载体的APRT缺陷型CHO细胞系中EGFP的表达分别提高了42%±6%和56%±9%;特别是长期传代培养时,转染弱化载体的APRT缺陷型细胞中EGFP表达量显著高于野生型CHO细胞(P<0.05);构建的基于APRT缺陷型CHO细胞系能够明显提高重组蛋白的长期表达稳定性。研究结果为建立高效稳定的CHO细胞表达系统提供了一种有效的细胞工程策略。     

CHO细胞表达系统启动子

中国仓鼠卵巢（Chinese hamsters ovary,CHO）细胞是目前重组蛋白质生产的首选宿主细胞。利用CHO细胞生产重组蛋白质,启动子是启动转基因转录的关键。核心启动子是RNA聚合酶与转录起始复合物集合的部位,分为集中型和分散型两种类型。目前,CHO细胞常用的启动子为病毒启动子、异源启动子、内源性和诱导性启动子等。也可以利用合成生物学及相关的数据库,人工设计合成启动子及鉴定新型启动子。本文综述了CHO细胞常用的启动子以及人工设计的合成启动子在CHO细胞中重组蛋白质表达方面的进展,为哺乳动物细胞选择合适的启动子,保证蛋白质表达量最大化,并确保长时间表达稳定性提供参考。     

CHO细胞表达系统研究新进展

中国仓鼠卵巢细胞(ChineseHamsterOvaryCell)是目前重组糖基蛋白生产的首选体系。本文综述近几年来该系统在生产基因工程药物方面的研究进展、存在问题和发展方向。     

中国仓鼠卵巢细胞表达外源蛋白研究进展

中国仓鼠卵巢细胞(Chinese hamster ovary,CHO)是一种生物制药技术的重要表达系统之一,在生物制药过程中应用较为广泛,但由于其应用成本较高,限制了发展,随年研究的深入,研究者们对于此系统进行了深入的探索,提高了该系统的表达效率,降低了应用成本。     

VPAC2在CHO细胞的表达及鉴定

PAC2是垂体腺苷酸环化酶激活多肽(Pituitary adenylate cyclase activating polypeptide,PACAP)和血管活性肠肽(vasoactive intestinal peptide,VIP)的共同受体,介导多种重要生物学功能。为获得稳定特异表达VPAC2的中国仓鼠卵巢(Chinesehamsterovary,CHO)细胞,将pcDNA-VPAC2表达载体转染CHO细胞,G418筛选转染阳性克隆,PACAP38标准品诱导阳性克隆细胞的胞内cAMP生成,筛选出对PACAP38最为敏感的阳性单克隆细胞株(VPAC2-CHO),运用RT-PCR、Westernblot和免疫荧光法检测VPAC2受体表达情况,利用VPAC2受体特异激动剂通过竞争性结合试验和促进胞内第二信使cAMP生成的活性检测实验证实,VPAC2-CHO特异表达有功能的VPAC2。Scatchard作图分析显示VPAC2-CHO的VPAC2受体密度为(1.1±0.2)pmol/mg膜蛋白,PACAP38与VPAC2的解离常数Kd值为(0.55±0.10)nmol/L。特异表达VPAC2受体细胞系的构建为深入研究该受体理化性质、生物学功能以及筛选、开发VPAC2受体新型特异激动剂和拮抗剂等研究奠定了基础。     

通过共表达转铁蛋白和细胞周期蛋白D1改造CHO细胞株

目的:对现有的CHO-DG44细胞株进行改造,得到在无血清培养基中更具生长优势的CHO宿主细胞株。方法:分别克隆转铁蛋白和细胞周期蛋白D1基因,构建共表达2种基因的pIRES质粒,转染CHO-DG44细胞株,筛选G418抗性克隆。结果与结论:得到3株G418阳性克隆株,其中转铁蛋白和细胞周期蛋白D1表达水平最高的S6与CHO-DG44相比,在无血清培养基中生长更快、密度更高。     

Production and purification of IgY antibodies from chicken egg yolk

The isolation of polyclonal antibodies from the serum of immunized mammals has significantly contributed to scientific research and diagnosis. The fact that recent technologies allow the production of antibodies in the yolk of eggs laid by hens, has led to the development of an alternative method for antibody generation that is less stressful to animals. As hens are kept under almost all their natural conditions, antibodies are isolated from the collected eggs; this technology is expected to become an interesting alternative to the conventionally serum-based techniques that eventually require to sacrifice the animal.Here we present a modified protocol for the isolation of IgY antibodies from immunized chickens and provide comparison between two chicken breeds in relative to IgY yield per egg. Our results show the possibility of generating large quantities of highly pure IgY from chicken eggs and also show large differences in the yield of IgY production between the two studied breeds. The results of this work indicate that IgY technology can be used for the production of primary antibodies for immunological work and disease diagnosis.     

Engineering CHO cell growth and recombinant protein productivity by overexpression of miR-7

The efficient production of recombinant proteins by Chinese Hamster Ovary (CHO) cells in modern bioprocesses is often augmented by the use of proliferation control strategies. The most common method is to shift the culture temperature from 37 °C to 28-33 °C though genetic approaches to achieving the same effect are also of interest. In this work we used qRT-PCR-based expression profiling using TLDA™ cards to identify miRNAs displaying differential expression 24 h after temperature-shift (TS) from 37 °C to 31 °C. Six miRNAs were found to be significantly up-regulated (mir-219, mir-518d, mir-126, mir-30e, mir-489 and mir-345) and four down-regulated (mir-7, mir-320, mir-101 and mir-199). Furthermore, qRT-PCR analysis of miR-7 expression over a 6 day batch culture, with and without TS, demonstrated decreased expression over time in both cultures but to a significantly greater extent in cells shifted to a lower culture temperature. Unexpectedly, when miR-7 levels were increased transiently by transfection with miR-7 mimic in CHO-K1 cells, cell proliferation at 37 °C was effectively blocked over a 96 h culture period. On the other hand, transient inhibition of endogenous miR-7 levels using antagonists had no impact on cell growth. The exogenous overexpression of miR-7 also resulted in increased normalised (per cell) production at 37 °C, though the yield was lower than cells grown at reduced temperature. This is the first report demonstrating a functional impact of specific miRNA disregulation on CHO cell behavior in batch culture and provides some evidence of the potential which these molecules may have in terms of engineering targets in CHO production clones. Finally, we report the cloning and sequencing of the hamster-specific cgr-miR-7.     

Effect of hydrocortisone on the production and glycosylation of an Fc-fusion protein in CHO cell cultures

Glucocorticoids are known to modulate various cellular functions such as cell proliferation, metabolism, glycosylation, and secretion of many proteins. We tested the effect of hydrocortisone (HC) on cell growth, viability, metabolism, protein production, and glycosylation of an Fc-protein expressing Chinese hamster ovary (CHO) cell culture. HC extended cell viability but impaired cell growth. The inhibitory effect on cell growth was dose-dependent and decreased when the glucocorticoid addition was delayed. When HC was added after 2 or 3 days of culture, an increase in glutamate consumption was observed, which was reversed by the glucocorticoid receptor antagonist mifepristone (Mif). Titer and specific productivity increased in the presence of HC. The increase in titer was only slightly reversed by Mif. On the other hand, Mif by itself induced an increase in titer to a level comparable to or higher than HC. Protein glycosylation was altered by the glucocorticoid in a dose- and time-dependent manner, with a shift to more acidic bands, which correlated with an increase in sialic acid moieties. This increase, which was not linked to a decrease in extracellular sialidase activity in HC-treated cultures, was reversed by Mif. Predictive models based on design of experiments enabled the definition of optimal conditions for process performance in terms of viability and titer and for the quality of the Fc-fusion protein in terms of glycosylation. The data obtained suggest a use of glucocorticoids for commercial production of Fc-fusion proteins expressed in CHO cells.     

Preparation of chicken IgY against recombinant E2 protein of bovine viral diarrhea virus (BVDV) and development of ELISA and ICA for BVDV detection

Bovine viral diarrhea virus (BVDV) infects cattle and may lead to persistent infection (PI). The PI animals harbor BVDV throughout their life and become immune tolerant against BVDV. Thus, diagnosis of this virus in herd is highly important. Recombinant E2 protein expression (using pET-32a in Escherichia coli) was confirmed by SDS-PAGE and Western blotting; then purified by Ni⁺ affinity chromatography. Chickens were immunized with BVDV-E2 protein, and IgY antibodies were extracted from egg yolk by PEG-6000. The peak titer of anti-BVDV-E2-IgY was 1:128,000 after the fifth immunization. IgY-based enzyme-linked immuno sorbent assay (ELISA) and immunochromatographic assay (ICA) were further developed. Coincidence of ELISA and ICA test with RT-PCR was 95.45 and 90.91%, respectively. The anti-BVDV-E2 IgY could be used in routine screening of BVDV infection. Besides, it can also be applicable while licensing and/or using live vaccines; screening of imported products containing bovine serum and strong surveillance of BVDV outbreaks.     

hK1-L-Fc融合蛋白在CHO细胞中的表达及其活性研究

为进一步改造重组人激肽释放酶1(hK1),以期提高其生物活性,制备了通过柔性接头相连接的重组人激肽释放酶1-L-IgG1 Fc融合蛋白(hK1-L-Fc)。采用重叠延伸PCR技术构建hK1-L-Fc融合基因,克隆至表达载体pcDNA3.1,在中国仓鼠卵巢细胞(CHO-S)中表达。利用Protein A 亲和层析柱纯化融合蛋白,SDS-PAGE、Western blotting、飞行时间质谱(MALDI-TOF-MS)、HPLC检测表达产物,底物法检测融合蛋白的体外活性。结果显示:成功构建pcDNA3.1-hK1-L-Fc重组表达载体;获得稳定表达融合蛋白的细胞株;无血清悬浮批式培养的表达量在0.7 mg/L以上;纯化的蛋白其纯度在95%以上,分子量约60 kDa;活性检测显示其比活性在9.2 U/mg以上,较hK1-Fc蛋白提高了18%以上。     

Anxa2- and Ctsd-knockout CHO cell lines to diminish the risk of contamination with host cell proteins

Chinese hamster ovary (CHO) cells have been used as host cells in the production of a range of recombinant therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. Host cell proteins (HCP) represent impurities that must be removed from therapeutic formulations because of their potential risks for immunogenicity. While the majority of HCP impurities are effectively removed in typical downstream purification processes, clearance of a small population of HCP remains challenging. In this study, we knocked out the Anxa2 and Ctsd genes to assess the feasibility of knockout approaches for diminishing the risk of contamination with HCP. Using the CRISPR/Cas9 system, Anxa2-, and Ctsd-knockout CHO cell lines were successfully established, and we confirmed the complete elimination of the corresponding HCP in cell lysates. Importantly, all knockout cell lines showed similar growth and viability to those of the wild-type control during 8 days of cultivation. Thus, knockout of unrequired genes can reduce contamination with HCP in the production of recombinant therapeutic proteins.     

A low-cost chemically defined protein free medium for a recombinant CHO cell line producing prothrombin

A chemically defined protein free medium, DF6S, was developed for the cultivation of a recombinant Chinese hamster ovary cell line (CHO2DS) producing human prothrombin in suspension batch culture. DF6S was formulated by optimizing DME/F12 with amino acids and supplementing the optimized DME/F12 with aurintricarboxylic acid, ethanolamine, ferric sulfate, Pluronic F68, putrescine and sodium pyruvate. From a seeding density of 2.3 × 10⁵ cells ml^–1, CHO2DS cells grown in suspension in DF6S medium reached a maximal cell density of 1.92 × 10⁶ cells ml^–1 with an accumulated prothrombin concentration of 16.7 mg l^–1 after 6 days in culture.     

A simple fractionation of chicken egg yolk yields a protein component that stimulates cell proliferation and differentiation in primary avian tendon cells

Summary An easily prepared and stable protein fraction from chick egg yolk promotes cell division (40 h generation time) and expression of procollagen (60% of total protein synthesis) in primary avian tendon cells in a serum-free medium. The activity of this yolk fraction (YF) is proteinaceous as reflected by its sensitivity to protease treatment. Yolk fraction is resolved into four major components on sodium dodecyl sulfate polyacrylamide gel electrophoresis with apparent molecular weights of 82,70,42,35 (× 10⁻³). Under nondenaturing conditions, YF runs as a mixture of high molecular weight aggregates on Sephacryl G-200. We postulate that the active part of YF could be the in ovo growth promoter for embryonic chick tendon cells. This work was supported in part by National Institutes of Health grant CA 37958 and in part by the Office of Health and Environmental Research, Office of Energy Research, U.S. Department of Energy, under Contract DE-AC03-76SF00098.     

人sApo2L-Fc的分子构建及其在CHO细胞中的表达

目的：构建人sApo2L-Fc分子,在中国仓鼠卵巢细胞（CHO）中表达有生物学活性的人Apo2L-Fc融合蛋白。 方法：将sApo2L-Fc基因克隆入pcDNA3.1（+）表达载体,重组质粒转化大肠杆菌DH5α。挑取阳性克隆扩大培养,提取质粒进行酶切鉴定;采用脂质体法将重组质粒转入CHO细胞,经G418加压筛选、ELISA检测,挑选表达较高的阳性转化子扩大培养;表达的sApo2L-Fc融合蛋白经Protein A亲和柱纯化,纯化产物用SDS-PAGE、Western Blotting检测样品的分子量及免疫原性,用L929细胞进行生物活性测定。 结果：酶切鉴定及测序显示重组子构建与预想一致;ELISA证实了sApo2L-Fc融合蛋白在CHO细胞中的表达;SDS-PAGE检测到纯化产物的分子量与理论分子量相符;在同样的位置,Western Blotting显示阳性;L929细胞测定：纯化产物的生物学活性达1.0×105IU/mg。 结论：构建了sApo2L-Fc的表达载体,并成功地在CHO中表达,表达的sApo2L-Fc融合蛋白具有生物学活性。